Trials / Completed
CompletedNCT00724373
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)
Retrospective Data Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 442 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed as a retrospective data review of medical records from participants selected from specialist secondary and tertiary care centers across the United Kingdom (UK), specializing in Hepatitis C treatment. The study is non-interventional and is designed to identify subgroups of Hepatitis C Virus (HCV) genotype 1 participants in the 'real world', including the relation between subgroup characteristics and treatment responsiveness.
Detailed description
Physicians will record information (from the time of first exposure to pegylated interferon alfa-2b and ribavirin) from the medical notes of participants who fit the inclusion criteria. To prevent selection bias, data are to be taken from the latest consecutive, unique participants seen by the physician over the previous 48 months. This provides a method of random sampling from a physician practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peginterferon alfa-2b (SCH 54031) | Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling. |
| DRUG | Ribavirin (SCH 18908) | Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-07-29
- Last updated
- 2015-09-25
- Results posted
- 2010-06-07
Source: ClinicalTrials.gov record NCT00724373. Inclusion in this directory is not an endorsement.